Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NEW VIDEO -
So did you get filled? I stacked a bunch of bids not getting filled.
I think they have to be getting sales of anaferon. looking forward to some sort of announcement and perhaps get this thing trading again. Trying to pick up cheapies.
Its live - talking about the MDX viewer. Very interesting so far.
LINK to LIVE Disucussion! Go to www.bioxytraninc.com There is a link to the Live stream at the market close.
Very few posts. Pretty sad the company doesnt talk. There is nothing to talk about $50 mil in cash just sitting there.
COVI-19 Article Mention Just out on CYDY - https://insiderfinancial.com/bioxtyran-otcmkts-bixt-licenses-phase-2-asset-for-covid-19-patients-after-finding-smoking-gun-journal-article/179757/
It in the valuation section of the article.
CYDY to Trump Podium - https://emerginggrowth.com/cytodyn-otcqb-cydy-experiencing-viral-boom-in-enrollment-may-lead-to-a-presidential-podium-announcement/ This makes a ton of sense.
This thing is flying. I think this article really helped put things into proportion. WE have the bet of breed technology AND we have 300K of potential daily supply. This is HUGE - revenue for this company is coming very soon! https://insiderfinancial.com/the-race-for-covid-19-tests-accelerating-after-fda-loosens-rules/179726/
TRUMPS FDA announcement! - Think it could be CYDY?
SECTOR PIECE - this is a definite read. Stocks in the testing sector moving. https://insiderfinancial.com/the-race-for-covid-19-tests-accelerating-after-fda-loosens-rules/179726/
MASSIVE NEW ARTICLE on Testing. AYTU nice mention. Looks like the blood test are way better than the nasal swab.
https://insiderfinancial.com/the-race-for-covid-19-tests-accelerating-after-fda-loosens-rules/179726/
Massive NEW ARTICLE on TESTING! - MUST SEE https://insiderfinancial.com/the-race-for-covid-19-tests-accelerating-after-fda-loosens-rules/179726/
They have the BEST Test on the market! this is a big deal.
WOW - NEW ARTICLE - https://marketnewsfirst.com/2020/03/11/prestigious-doctor-calls-lack-of-publicity-about-drug-effectiveness-criminal/
People need to pay attention to this stuff.
The article did an update of the last investor call.
NEW ARTICLE - https://www.genengnews.com/a-lists/how-to-conquer-coronavirus-top-35-treatments-in-development/ List the various treatment options and we are among them.
MORE EXPOSURE - Another article on Coronavirus mentions company. https://www.genengnews.com/a-lists/how-to-conquer-coronavirus-top-35-treatments-in-development/
ARTICLE MOVING PRICE - a lot of people that read this article that moved it. https://insiderfinancial.com/top-coronavirus-stocks-backed-by-scientific-evidence/179657/
The float is way less than advertised. The "Real Float" is way less just looking at the movement today. This stock can really move. Its thinly traded and management is secure with their positioning.
Great Article - this could definitively be a coronavirus answer if they can get some development funds. Sweet find.
Another article that seem to copy the one you showed me didnt mention NBIO but it looks good. https://www.genengnews.com/a-lists/how-to-conquer-coronavirus-top-35-treatments-in-development/
HUGE VOLUME TODAY. GREAT article mentioning BIXT
https://insiderfinancial.com/top-coronavirus-stocks-backed-by-scientific-evidence/179657/
MONSTER ARTICLE! - CYDY and GILD combination in Corona - Must read https://insiderfinancial.com/top-coronavirus-stocks-backed-by-scientific-evidence/179657/
BETTER RED CHIP INTERVIEW -
NEW RED CHIP VIDEO - was trolling on internet and look what popped up.
Love this article! Very informative and talks more about the mechanism of action. We have a winner indeed.
STOPS CANCER METASTASIS COLD in its tracks!
Its the protocol 3 + 3 design. Dose three people no Dose limiting toxicity after three then up dosage. Then after the next 3 they can go to 700. After 3 at 700 phase 1b is DONE and Phase 2a continues. This data is phenomenal at the lower doses. What happens at higher doses = spectacular.
That board that went against him is gone. there is a new reconstituted board and Scot Kelly is leading and he is an absolute rock star with steadfast vision for the company. Their vision expelled Pestel and as we can see Pestell was simply too conservative which is why they didnt get people in the trial sooner. If your CMO doesnt agree the only course of action is draconian.
I put to you - has Nader really had bad ideas? well other than the financings. We all second guess the financings but we also dont have the level of information he has so its difficult to gauge would we have made a better decision.
you Said significant shareholder - like 6 figure or 7 figure shareholder.
Quite the find. Its really to believe that these african deals are bogus but when you see it on an official site it really helps believe its a real deal. Thank you. keep sleuthing.
NEW VIDEO OUT! FORGET CULPER! Proactive put a new video release out.
https://www.proactiveinvestors.com/companies/news/912806/cytodyn-forms-partnership-with-chinese-medical-services-provider-to-fight-deadly-coronavirus-912806.html
Lots of detail and clarity of the coronavirus. They are going to see if it works FIRST and then negotiate - LOVE IT!
900K offer slap was pretty impressive! The stock is really waking up out of a slumber. something is really cooking. Anyone put together a good DD package?
This seems like a really good story. been in this stock forever and rode it up to a penny and then started averaging downd and down and down and down but now it seems to be turning the corner. Never could figure out how blockchain stocks are tied to bitcoin but they are I guess. this is a real one.
Longen WEBSITE = REAL DEAL
http://www.longengroup.com/
NEW ARTICLE! https://www.bioprocessonline.com/doc/the-perilous-development-of-a-potential-biologic-blockbuster-0001
HC Wainwright Reiterates BUY!
https://www.smarteranalyst.com/new-blurbs/h-c-wainwright-sticks-to-its-buy-rating-for-cytodyn-cydy/
CytoDyn, Inc.
CYDY: Price: $1.31; Market Cap (M): $585
Rating: Buy; Price Target: $1.50
Yi Chen, Ph.D. CFA
Raghuram Selvaraju, Ph.D.
Regulatory Filing Completion Imminent; Phase 2 Cancer Basket Trial Filed; Reiterate Buy
Click here for complete report and disclosures
Completion of leronlimab filing in HIV infection this month. Yesterday, CytoDyn provided an update on its clinical development through an investor call. Management indicated that the Biologics License Application (BLA) filing for the leronlimab 700mg weekly dose as a combination therapy with highly active antiretroviral therapy (HAART) for HIV-infected patients is slated to be completed in February 2020. Leronlimab is a humanized IgG4 mAb that blocks CCR5 receptor and prevents HIV-1 from entering and infecting immune cells. The FDA has granted rolling review of the leronlimab BLA; as a reminder, the non-clinical portion of the BLA was initially filed in March 2019. Once the required chemistry, manufacturing and controls (CMC) and clinical data sections of the BLA are completed, the FDA should complete the review process within six months under the Fast Track designation. Upon regulatory approval, leronlimab is contracted to be commercialized by Vyera Pharmaceuticals in the U.S., who shall pay royalty and milestone payments to CytoDyn under the license agreement. In the wake of this update, we reiterate our Buy rating and $1.50 price target.
Six breast cancer patients enrolled; solid tumor basket trial filed. Management indicated that a total of six patients have been enrolled in the clinical trials evaluating leronlimab for the treatment of metastatic triple-negative breast cancer (mTNBC) and metastatic breast cancer (MBC). The company has previously reported that the first mTNBC patient continued to show no detectable levels of circulating tumor cells (CTC) or putative metastatic cells in the peripheral blood following 16 weeks of treatment with leronlimab in combination with carboplatin. The second mTNBC patient enrolled showed no detectable levels of CTC with leronlimab in combination with carboplatin after two weeks of treatment. The third mTNBC patient had CTC drop to zero after two weeks of treatment, confirming a rapid response to leronlimab. The patient that has Stage 4 HER2+ MBC with metastasis to the liver, lung and brain demonstrated no new metastasis in the brain following two months of treatment with leronlimab (one 700mg dose each week). With positive data from the first four patients, CytoDyn has filed a Phase 2 protocol with the FDA for a basket trial evaluating leronlimab in 22 different solid tumor cancers. According to the protocol, the study will enroll 30 patients with CCR5+ locally advanced or metastatic solid tumors, who are to receive a once-weekly dose of 350mg leronlimab delivered subcutaneously. Preliminary results may be generated within three to four weeks following the initial treatment. We feel these data could further support the notion that CCR5 blockade by leronlimab could have a multitude of anti-tumor effects including inhibition of immune inhibitory T-cells, promotion of anti-tumor activity by macrophages, and inhibition of angiogenesis in tumors. We note that the use of leronlimab in oncology is currently not included in our valuation of the company, and positive results in treatment of various cancers could drive considerable upside to our price target.
Chinese licensing deal to be finalized. Management announced that CytoDyn has entered a non-binding agreement with a Chinese biopharma firm to develop leronlimab for the treatment of cancer and potentially coronavirus infections in China. Given the partner’s experience with the Chinese regulatory agency and its ownership of tier-1 hospitals, CytoDyn believes that leronlimab could be advanced rapidly into clinical trials in China once the deal is finalized. In our view, this licensing deal could bring non-dilutive capital to CytoDyn via potential near- to medium-term milestone and royalty payments.
Equity financing completed; debt financing next. Earlier this week, the company filed an 8-K disclosing a private placement of Series D convertible preferred stock of $7.6M, with 3.8M warrants. The preferred stock has a conversion price of $0.80 per share, and the warrant’s exercise price is $1.00 per share. The company is also exploring the opportunity of a debt offering, which may be completed in the coming months.
Valuation and risks. Our 12-month price target is derived from an estimated market value of the firm at $902M. It includes a discounted cash flow (DCF)-based asset value of $910M for leronlimab in the HIV indication alone, with 15% discount rate, 2% terminal growth rate, 85% probability of success, and excludes $8M debt. Using 600M fully diluted shares, this leads to a value of approximately $1.50 per share. Risks include, but are not limited to: (1) failure of leronlimab in clinical trials; (2) failure of leronlimab to secure regulatory approval; (3) failure of leronlimab to achieve commercial success due to market size, penetration rate, and/or competition; and (4) dilution risk.
Yi Chen, Ph.D. CFA
212-916-3971
ychen@hcwresearch.com
Raghuram Selvaraju, Ph.D.
212-916-3966
rselvaraju@hcwresearch.com
Get a lot or a little? This thing is really moving. out of all the corona virus stock this is the real deal with real sales potential.
SHARE REDUCTION COMING! - Key Tweet People seem to have missed
$TGGI - has been reinstated by OTCmarkets and will begin uploading the 6 missing reports and become current over the next few weeks.
— Trans Global Group (@transggi) January 22, 2020
These notes that everyone is fussing about are related to the outgoing mgt. If you think they are selling today you have another thing coming. To make this announcement and sell you cannot do that. They are considered affiliates for at least 90 days. This selling are just exiting shareholders. It looks like dilution but its not. There was one shareholder that had 4.0 million in this company and bid the stock up. I think he just wanted to liquidate. Its great that $AVOP got attention lets see what the new crew does with it.
Did you read the ARTICLE ON $AVOP? http://psinvestor.com/av1-group-otc-avop-and-the-quest-for-more-info-on-omid-holdings/ Maybe the Omid deal is closing.
This CYDY article didnt get too much traction - FOLLOW THIS AUTHOR
https://seekingalpha.com/article/4314267-real-value-of-breakthrough-therapy-designation
$8.3 billion is the value of a BTD approval on average and CYDY has one of the biggest patient populations ever. there are unbelievers out there right now that need to quit flipping stock and let this be a ride of a lifetime.
One catalyst not mentioned. What about all the analysts that could upgrade the stock. Something that quadruples gets on an analysts radar. Dont forget about that catalyst.
Technically $1.20 is a major resistance level. I think that is history next week. They are continuing to make reports on patients. Its time for another report possibly next week then the BLA filing. Too many catalysts to ignor. Then what about non-dilutive funding. No one believed him when he had an $100 mil licensing deal in Sept. If he get the 40 - 50 mil it will be sweet. Also no one talking about licensing deal. He mentioned that as well. Its sick how many catalysts.
FOLLOW
Thanks for the $LBTI support. I still think there is a short out there for 40K shares so long and strong.